platieshop2013good.ru
Главная Верапамил при аллергии на гистамин

Подтяжка ягодиц в картинках

Вышел из ануса геморрой беременна


Читать дальше

Медицина.хрон.цистит.уретрит

Уфа научный институт глазных болезней


Читать дальше

Il-13 при псориазе


узвар изжога

1. Бадокин В.В. Место лефлуномида в комплексной терапии псориатического артрита // Фарматека 2008. - № 6. - с. 16-20.

2. Беляев Г.М., Рыжко П.П. Псориаз. Псориатическая артропатия: (этиология, патогенез, диагностика, лечение, профилактика) М.: МЕДпресс-информ, 2005. - 3-е изд.; доп. — с. 266.

3. Быковская С.Н., Насонов Е.Л. Роль дефектов иммуносупрессии в развитии аутоиммунных заболеваний // Научно-практическая ревматология. 2005. -№4. -с. 81-84.

4. Голоусенко И.Ю., Фадеева В.И., Аккаль Омран. Случай рупиоидного псориаза с артропатией // Вестн. дерматол. и венерол. 1984. - N 3. — с. 74 -75.

5. Логинова Е.Ю., Коротаева Т.В. Ранний псориатический артрит // Научно-Практическая ревматология 2008. - № 6. - с. 47-55.

6. Маркушева Л.И., Самсонов В.А., Фомина Е.Е., Чистякова И.П. Уровень сывороточного некроза опухоли при псориазе // Вестн. дерматол. и венерол. -1997.-№3.- с. 8-11.

7. Методические рекомендации по терапии больных псориазом // Государственный научный центр дерматовенерологии Росмедтехнологи. -М., 2008. с. 4-8.

8. Методические рекомендации №3 // Спектр клинических проявлений псориатического артрита. М., 2006. - с. 23-24.

9. Михайленко A.A., Коненков В.И., Базанов Г.А., Покровский В.И. Руководство по клинической иммунологии и аллергологии, иммуногенетике, иммунофармакологии. (для врачей общеклинической практики)- М.: ГЭОТАР МЕДИЦИНА, 2005. с. 26.

10. Мордовцев В.Н., Алиева П.М., Сергеев A.C. / Заболевания кожи с наследственным предрасположением. Махачкала, 2002. - с. 260.

11. Насонов Е.Л. Клинические рекомендации. Ревматология. М.: ГЭОТАР I МЕДИЦИНА, 2008.-с. 110-111.t ,

12. Насонова В.А., Бунчук Н.В. // Избранные лекции по клинической ревматологии -М.: Медицина, 2001. с. 95-97.

13. Нелюбин Е.В. // Иммунологические нарушения и апоптотическая реактивность лимфоцитов периферической крови при псориазе. Автореф.: 14.00.36-Е., 2007.-с. 8.

14. Селютин А.В., Сельков С.А. Методы определения содержания Т-регуляторных клеток в периферической крови. Лабораторная диагностика.-2008.- Т.20, №4. с. 19-21.

15. Реброва О.Ю. // Статистический анализ медицинских данных. Применение пакета прикладных программ STATISTICA. М.: МедиаСфера. -2002.-с. 185.

16. Скрипкин Ю.К. // Кожные и венерические болезни. Руководство для врачей. -Т.2. -М.: Медицина, 1995. с. 179-190.

17. Соколовский Е.В., Аравийская Е.Р., Монахов К.Н. Дерматовенерология.-СПб: Академия, 2005. с. 227.

18. Тотолян А.А., Фрейдлин И.С. Клетки иммунной системы. СПб: Наука. - 2000. -ТI-II. - с. 28-33.

19. Ярилин А.А., Донецкова А.Д. Естественные регуляторные Т-клетки и фактор FOXP3 // Иммунология. 2006. - Т.27, №3. - с.176-188.

20. Шегай М.М., Кешилева З.Б., Акышбаева Г.А. Роль некоторых цитокинов в развитии псориаза // Вестн дерматол и венерол. 1998. - Т. 5, №7. - с. 13 -21.

21. Abbas А.К., Murphy К.М., Sher A. Functional diversity of helper T lymphocytes // Nature. 1996. - Vol. 383. - p. 787-793.

22. Allen M.H., Veal C., Faassen A., Powis S.H., Vaughan R.W., Trembath R.C., Barker J.N. A non-HLA gene within the MHC in psoriasis // Lancet. 1999. -Vol. 353.-p. 1589-1590.

23. Annunziato F., Galli G., Cosmi L., Romagnani P., Manetti R., Maggi E., Romagnani S. Molecules associated with human Thl or Th2 cells // Eur. Cytokine Netw. 1998. -Vol. 9 (3 Suppl). -p. 12-16.

24. Annunziato F., Cosmi L., Galli G., Beltrame C., Romagnani P., Manetti R., Romagnani S., Maggi E. Assessment of chemokine receptor expression by human Thl and Th2 cells in vitro and in vivo // J. Leukoc. Biol. 1999. - Vol. 65, N 5. - p. 691-699.

25. Arias A., Giles B., Eiermann T., Sterry W., Pandey J. Tumor necrosis factor-alpha gene polymorphism in psoriasis // Exp Clin Immunogenet. 1997. - N 14. -p. 118-122.

26. Asadullah K., Sterry W., Stephanek K., Jasulaitis D., Leupold M., Audring H., Volk H.D., Docke W.D. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach// J Clin Invest. 1998. -Vol. 101. -p. 783 - 794.

27. Asadullah K., Eskdale J., Wiese A., Gallagher G., Friedrich M., Sterry W. Interleukin-10 promoter polymorphism in psoriasis // J Invest Dermatol. 2001. -Vol. 116.-p. 975-978.

28. Austin L.M., Coven T.R., Bhardwaj N., Steinman R., Krueger J.G. Intraepidermal lymphocytes in psoriatic lesions are activated GMP-17(TLA-1)+CD8+CD3+ CTLs as determined by phenotypic analysis // J Cutan Pathol. -1998.-N25.-p. 79- 88.

29. Bacon K.B., Premack B.A., Gardner P., Schall T.J. Activation of dual T cell signaling pathways by the chemokine RANTES // Science. 1995. - Vol. 5231, N 269.-p. 1727- 1730.

30. Baecher-Allan C., Brown J.A., Freeman G.J., Hafler D.A. CD4+CD25high regulatory cells in human peripheral blood// J Immunol. 2001. - Vol. 167, N 3. -p. 1245-1253.

31. Bagga A., Menon S., Hari P., Mantan M., Dinda A. Nephrotic syndrome preceding psoriasis in children // Pediatr Nephrol. 2007. - Vol. 22, N 9. - p. 1373-1376.

32. Baggiolini M., Walz A., Kunkel S.L. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils // J. Clin. Invest. 1989. -N84.-p. 1045-1049.

33. Baggiolini M., Dewald B., Moser B. Interleukin-8 and related chemotactic cytokines CXC and CC chemokines // Adv. Immunol. - 1994. - N 55. - p. 97 -179.

34. Baggiolini M. Chemokines and leukocyte traffic // Nature. 1998. - Vol. 6676, N392.-p. 565-568.

35. Baker B.S., Powles A.V., Valdimarsson H., Fry L. An altered response by psoriatic keratinocytes to gamma interferon // Scand J Immunol. 1988. - N 28. -p. 735 - 740.

36. Baker B.S., Fry L. The immunology of psoriasis // Br J Dermatol. 1992. -N126.-p. 1-9.

37. Bellinghausen I., Klostermann B., Knop J., Saloga J. Human CD4+CD25+ T i cells derived from the majority of atopic donors are able to suppress Thl and Th2cytokine production // J Allergy Clin Immunol. 2003. - Vol. 111, N 4. - p. 862868.

38. Bianchi L., Farrace M.G., Nini G., Piacentini M. Abnormal Bcl-2 and "tissue" transglutaminase expression in psoriatic skin // J Invest Dermatol. 1994. -Vol. 103.-p. 829-833.

39. Boehncke W.H. Immunomodulatory drugs for psoriasis //BMJ. 2003. - N 327.-p. 634-635.

40. Bonifati C., Ameglio F. Cytokines in psoriasis // Int J Dermatol. 1999. -N 38.-p. 241-251.

41. Bos J.D., Hulsebosch H.J., Krieg S.R., Bakker P.M., Cormane R.H. Immunocompetent cells in psoriasis. In situ immunophenotyping by monoclonal antibodies // Arch Dermatol Res. 1983. - N 275. - p. 181-189.

42. Bos J.D., Hagenaars C., Das P.K., Krieg S.R., Voorn W.J., Kapsenberg M.L. Predominance of "memory" T cells (CD4+, CDw29+) over "naive" T cells (CD4+, CD45R+) in both normal and diseased human skin // Arch Dermatol Res. 1989. -Vol. 281.-p. 24-30.

43. Bos J.D., De Rie M.A. The pathogenesis of psoriasis: immunological facts and speculations // Immunol Today. 1999. - N 20. - p. 40-46.

44. Brandrup F., Green A. The prevalence of psoriasis in Denmark // Acta Derm Venereol. 1981. - Vol. 61- p. 344-346.

45. Broxmeyer H.E., Kim C.H. Regulation of hematopoiesis in a sea of chemokine family members with a plethora of redundant activities // Exp. Hematol. 1999. - Vol. 27, N. 7. - p. 1113-1123.

46. Chang E.Y., Hammerberg C., Fisher G., Baadsgaard O., Ellis C.N., Voorhees J.J., Cooper K.D. T cell activation is potentiated by cytokines released by lesional psoriatic, but not normal, epidermis // Arch Dermatol. 1992. - Vol. 128.-p. 1479-1485.

47. Chang J:C., Smith L.R., Froning K.J., Kurland H.H., Schwabe B.J., Blumeyer K.K., Karasek M.A., Wilkinson D.I., Farber E.M., Carlo D.J., Brostoff S.W. Persistence of T-cell clones in psoriatic lesions // Arch Dermatol. 1997. -Vol. 133.-p. 703-708.

48. Chang Y.T., Tsai S.F., Lin M.W., Liu H.N., Lee D.D., Shiao Y.M., Chin P.J., Wang WJ. SPR1 gene near HLA-C is unlikely to be a psoriasis susceptibility gene// Exp Dermatol. 2003. - Vol. 12. - p. 307-314.

49. Chen Z., Herman A., Matos M., Mathis D., Benoist C. Where CD4+CD25+ T reg cells impinge on autoimmune diabetes // J Exp Med. 2005. - Vol. 202, N 10. -p. 1387-1397.

50. Christophers E., Mrowietz U. The infammatory infitlrate in psoriasis // Clin Dermatol. 1995.-Vol. 13-p. 131-135.

51. Christophers E. Psoriasis epidemiology and clinical spectrum // Clin Exp Dermatol.-2001. - Vol. 26.-p. 314-320.

52. Creamer D., Sullivan D., Bicknell R., Barker J. Angiogenesis in psoriasis // Angiogenesis. 2002. -N 5.- p. 231-236.

53. Clark-Lewis I., Dewald B., Geiser T., Moser B., Baggiolini M. Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its Nterminus is modified with Glu-Leu-Arg // Proc. Natl. Acad. Sci. USA. 1993. -Vol. 90, N8.-p. 3574—3577.

54. Clark-Lewis I., Kim, K.S., Rajarathnam K., Gong J.H., Dewald B., Moser B. Structure-activity relationships of chemokines // J Leukoc Biol 1995. - Vol. 5745, N 522. - p. 703-711.

55. Cochran B.J., Reffel A.C., Stiles C.D. Molecular cloning of gene sequences regulated by platelet-derived growth factor // Cell. 1983. - N 33. -p. 939-947.

56. Cook D.N., Beck M.A., Coffman T.M., Kirby S.L., Sheridan J.F., Pragnell I.B, Smithies O. Requirement of MIP-1 alpha for an inflammatory response to viral infection // Science. 1995. - Vol. 5230, N 269. - p. 1583-1585.

57. Cook D.N. The role of MIP-1 alpha in inflammation and hematopoiesis // J. Leukoc. Biol. 1996. - Vol. 59, N 1. - p. 61-66.

58. Cooper K.D., Hammerberg C., Baadsgaard O., Elder J.T., Chan L.S., Sauder D.N., Voorhees J.J., Fisher G. IL-1 activity is reduced in psoriatic skin. Decreased IL-1 alpha and increased nonfunctional IL-1 beta // J Immunol. 1990. Vol. 144. -p. 4593-4603.

59. Cyster J.G. Chemokines and cell migration in secondary lymphoid organs // Science. -1999. Vol. 5447, N 286. - p. 2098-2102.

60. Darrasse-Jéze G., Klatzmann D., Charlotte F., Salomon B.L., Cohen J.L. CD4+CD25+ regulatory/suppressor T cells prevent allogeneic fetus rejection in mice // Immunol Lett. 2006. - Vol. 102, N 1. - p. 106-109.

61. Detmar M., Orfanos C.E. Tumor necrosis factor-alpha inhibits cell proliferation and induces class II antigens and cell adhesion molecules in cultured normal human keratinocytes in vitro // Arch Dermatol Res. 1990. - Vol. 282. -p. 238-245.

62. Dewald B., Moser B., Barella L., Schumacher C., Baggiolini M., Clark-Lewis I. IP-10, a gamma-interferon-inducible protein related to interleukin-8, lacks neutrophil activating properties // Immunol. Lett. 1992. -N 32. - p. 81-84.

63. Dieu-Nosjean M.C., Massacrier C., Homey B., Vanbervliet B., Pin J.J., Vicari A., Lebecque S., Dezutter-Dambuyant C., Schmitt D., Zlotnik A., Caux C.132

64. Macrophage inflammatory protein 3-alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors // J Exp Med. 2000. - Vol. 192. - p. 705-718.

65. Ekholm E., Egelrud T. Stratum corneum chymotryptic enzyme in psoriasis // Arch Dermatol Res. 1999. - Vol. 291. -p. 195-200.

66. Elder J., Nair R., Henseler T., Jenisch S., Stuart P., Chia N., Christophers E., Voorhees J. The genetics of psoriasis 2001: the odyssey continues // Arch Dermatol. 2001. - Vol. 137. -p. 1447-1454.

67. Enarsson K., Lundin B.S., Johnsson E., Brezicka T., Quiding-Járbrink M. CD4+ CD25 high regulatory T cells reduce T cell transendothelial migration in cancer patients // Eur J Immunol. 2007. - Vol. 37, N 1. -p. 282-291.

68. Esche C., de Benedetto A., Beck L.A. Keratinocytes in Atopic Dermatitis: Inflammatory Signals // Curr Allergy Asthma Rep. 2004. - Vol. 4, N 4. - p. 276284.

69. Farber J.M. Mig and IP-10: CXC chemokines that target lymphocytes // J. Leukoc. Biol. 1997. - Vol. 61, N 3. - p. 246-257.

70. Feng Y., Broder C.C., Kennedy P.E., Berger E.A. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein-coupled receptor // Science. 1996. - Vol. 272. - p. 872-877.

71. Fierlbeck G., Rassner G., Muller C. Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations // Arch Dermatol. 1990. -Vol. 126. - p. 351-355.

72. Forster R., Mattis A.E., Kremmer E., Wolf E., Brem G., Lipp M. A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs133and specific anatomic compartments of the spleen 11 Cell. 1996. - Vol. 87, N 6. -p. 1037-1047.

73. Fredriksson T., Peterson V. Severe psoriasis oral therapy with a new retinoid // Dermatológica. - 1978. - Vol. 157, N 4. -p. 238-244.

74. Fujimura T., Okuyama R., Ito Y., Aiba S. Profiles of FOXP3+ regulatory T cells in eczematous dermatitis, psoriasis vulgaris and mycosis fungoides // Br J Dermatol. 2008. - Vol. 158, N 6. -p. 1256-1263.

75. Gerard C., Frossard J.L., Bhatia M., Saluja A., Gerard N.P., Lu B., Steer M., Targeted disruption of the beta-chemokine receptor CCR1 protects against pancreatitis-associated lung injury // J. Clin. Invest. 1997. - Vol. 100, N 8. - p. 2022-2027.

76. Ghoreschi K., Weigert C., Rócken M. Immunopathogenesis and role of T cells in psoriasis// Clin Dermatol. 2007. -Vol. 6, N 25. - p. 574-580.

77. Gillitzer R., Ritter U., SpandauU., Goebeler M., Brocker E.B. Differential expression of GRO-alpha and IL-8 mRNA in psoriasis: a model for neutrophil migration and accumulation in vivo // J Invest Dermatol. 1996. - Vol. 107. - p: 778-782.

78. Gladman D.D. Psoriatic arthritis // Oxford textbook of rheumatology/ Eds. Maddison P.J., Isenberg D.A., Woo P., Glass D.N. N-Y.: Oxford University Press. - 1998.-p. 1071-1084.

79. Goffe B., Cather J.C. Etanercept: An overview // J Am Acad Dermatol. -2003. Vol. 49, N 2. - p. 105-111.

80. Gomi T., Shiohara T., Munakata T., Imanishi K., Nagashima M. Interleukin 1 alpha, tumor necrosis factor alpha, and interferon gamma in psoriasis // Arch Dermatol. 1991. - Vol. 127, N 6. - p. 827-830.

81. Gottlieb A.B. Infliximab for psoriasis // J Am Acad Dermatol. 2003. -Vol. 49, N 2.-p. 112-117.

82. Groves R.W., Giri J., Sims J., Dower S.K., Kupper T.S. Inducible expression of type 2 IL-1 receptors by cultured human keratinocytes. Implications for IL-1-mediated processes in epidermis // J Immunol. 1995. - Vol. 154. - p. 4065-4072.

83. Guillaudeux T., Janer M., Wong G.K., Spies T., Geraghty D.E. The complete genomic sequence of 424,015 bp at the centromeric end of the HLA class I region: gene content and polymorphism II Proc Natl Acad Sci USA. 1998. -Vol. 95.-p. 9494-9499.

84. Henseler T., Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris // J Am Acad Dermatol. 1985. -Vol. 13.-p. 450-456.

85. Henseler T. Genetics of psoriasis // Arch Dermatol Res. 1998. - Vol. 290, N9.-p. 463-476.

86. Holm S.J., Carlen L.M., Mallbris L., Stahle-Backdahl M., O'Brien K.P. Polymorphisms in the SEEK1 and SPR1 genes on 6p21.3 associate with psoriasis in the Swedish population // Exp Dermatol. 2003. - Vol. 12. - p. 435-444.

87. Homey B., Meller S. Chemokines and other mediators as therapeutic targets in psoriasis vulgaris// Clin Dermatol. 2008. - Vol. 26, N 5. - p. 539-545.

88. Horuk R., Chitnis C.E., Darbonne W.C., Colby T.J., Rybicki A., Hadley T.J., Miller L.H., A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor // Science. 1993. - Vol. 5125, N 261. - p. 11821184.

89. Hu A., Du J., Li J., Liu J. Oridonin promotes CD4+/CD25+ Treg differentiation, modulates Thl/Th2 balance and induces HO-1 in rat splenic lymphocytes // Inflamm Res. 2008. - Vol. 57, N 4. - p. 163-170.

90. Jacob S.E., Nassiri M., Kerdel F.A., Vincek V. Simultaneous measurement of multiple Thl and Th2 serum cytokines in psoriasis and correlation with disease severity // Mediators Inflamm. -2003. Vol. 12, N 5. -p. 309-313.

91. Jiao Y., Xu H., Li H., Li X. Mesangial proliferative glomerulonephritis with or without IgA deposits: the morphological characters in psoriasis vulgaris // Nephron Clin Pract. 2008. - Vol. 108, N 3. - p. 221-225.

92. Joosten S.A., Ottenhoff T.H. Human CD4 and CD8 regulatory T cells in infectious diseases and vaccination // Hum Immunol. 2008. - Vol. 69, N 11. - p. 760-770.

93. Kadunce D.P., Krueger G.G. Pathogenesis of psoriasis // Dermatol Clin. -13: 1995.-p. 723-737.

94. Kelly R., Marsden R.A., Bevan D. Exacerbation of psoriasis with GM-CSF therapy // Br J Dermatol. 1993. -Vol. 128. - p. 468-469.

95. Kirby B., Griffiths C.E. Psoriasis: the future // Br J Dermatol. 2001. - Vol. 144, N58.-p. 37-43.

96. Korn T., Anderson A.C., Bettelli E., Oukka M. The dynamics of effector T cells and FOXP3+ regulatory T cells in the promotion and regulation of137autoimmune encephalomyelitis // J Neuroimmunol. 2007. - Vol. 191, N 1-2. - p. 51-60.

97. Krishnan B.R., Jamry I., Chaplin D.D. Feature mapping of the HLA class I region: localization of the POU5F1 and TCF19 genes // Genomics. 1995. - Vol. 30.-p. 53-58.

98. Krueger G.G., Jorgensen C.M. Experimental models for psoriasis // J Invest Dermatol. 1990. - Vol. 95. - p. 56-58.

99. Krueger J.G. The immunologic basis for the treatment of psoriasis with new biologic agents// J Am Acad Dermatol. 2002. - N 46. - p. 1-23.

100. Krueger G.G., Callis K.P. Development and use of alefacept to treat psoriasis // J Am Acad Dermatol. 2003. - Vol. 49, N 2. - p. 87-97.

101. Ku D.H., Chang C.D., Koniecki J., Cannizzaro L.A., Boghosian-Sell L., Alder H., Baserga R. A new growth-regulated complementary DNA with the sequence of a putative trans-activating factor // Cell Growth Differ. 1991. - N 2. -p. 179-186.

102. Kuchroo V.K., Sarvetnick N., Hafler D.A., Nicholson L.B. Cytokines and Autoimmune Diseases. 2002.- p. 170-180.

103. Kyewski B., Suri-Payer E. CD4+CD25+ Regulatory T cells: Origin, Function and Therapeutic potential. Berlin: Springer- Verlag Berlin Heidelberg. -2005. - p. 13-15.

104. Lecewicz-Torun B., Pietrzak A., Rolinski J., Brzozowski W. The peripheral blood lymphocyte pattern in psoriasis preceded by an infection // Med Sei Monit. — 2001.-Vol. 5, N7.-p. 889-893.

105. Lee Y.C. Synergistic effect of various regulatory factors in Thl/Th2 balance; immunotherapeutic approaches in asthma // Int J Biomed Sei. 2008. - Vol. 4, N l.-p. 8-13.

106. Leigh I.M., Navsaria H., Purkis P.E., McKay I.A., Bowden P.E., Riddle P.N. Keratins (K16 and K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro // Br J Dermatol. 1995. - N 133. - p. 501-511.

107. Loetscher P., Uguccioni M., Bordoli L., Baggiolini M., Moser B., Chizzolini C., Dayer J.M. CCR5 is characteristic of Thl lymphocytes //Nature. 1998. - Vol. 6665, N391.-p. 344-345.

108. Loetscher M., Loetscher P., Brass N., Meese E., Moser B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization // Eur. J. Immunol. 1998. - Vol. 28, N 11. - p. 3696-3705.

109. Leonardi G.L. Efalizumab: An overview // J Am Acad Dermatol. 2003. -Vol. 49.-p. 98-104.

110. Lomholt G. Psoriasis: Prevalence, spontaneous course, and genetics: a census study on the prevalence of skin diseases on Faroe Islands // GEC Gad. -1963. Copenhagen. - 2-12.r i

111. Lusti-Narasimhan M., Power C.A., Allet B., Alouani S., Bacon K.B., Mermod J.J., Proudfoot A.E., Wells T.N. Mutation of Leu25 and Val27 introduces CC chemokine activity into interleukin-8 // J. Biol. Chem. 1995. - Vol. 270. - p. 2716-2721.

112. Ma Q., Jones D., Springer T.A. The chemokine receptor CXCR4 is required for the retention of B lineage and granulocytic precursors within the bone marrow microenvironment // Immunity. 1999. - Vol. 10, N 4. - p. 463-471.

113. Macchioni P., Boiardi L., Meliconi R., Pulsatelli L., Maldini M.C., Ruggeri R., Facchini A., Salvarani C. Serum chemokines in patients with psoriatic arthritis treated with cyclosporin A//J Rheumatol. 1998. - Vol. 2, N 25. - p. 320-325.

114. Mahmoud F., Abul H., al Saleh Q., Hassab-el Naby H., Kajeji M., Haines D., Burleson J., Morgan G. Elevated B-lymphocyte levels in lesional tissue of non-arthritic psoriasis// J Dermatol. 1999. - Vol. 7, N 26. - p. 428-433.

115. Maloy K.J., Salaun L., Cahill R., Dougan G., Saunders N.J., Powrie F. CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms// J Exp Med. -2003. Vol. 1, N 197. - p. 111-119.

116. Mantovani A. /Chemokines. Karger, Basel. - 1999. - p. 20-34.

117. Mastroianni A., Minutilli E., Mussi A., Bordignon V., Trento E., D'Agosto G., Cordiali-Fei P., Berardesca E. Cytokine profiles during infliximab monotherapy in psoriatic arthritis// Br J Dermatol. 2005. - Vol. 153, N 3. - p. 531-536.

118. McGrath K.E., Koniski A.D., Maltby K.M., McGann J.K., Palis J. Embryonic expression and function of the chemokine SDF-1 and its receptor, CXCR4 // Dev. Biol. 1999. - Vol. 213, N 2. - p. 442^156.

119. Mehlis S.L., Gordon K.B. The immunology of psoriasis and biologic immunotherapy // J Am Acad Dermatol. 2003. -N 49. - p. 44-50.

120. Menssen A., Trommler P., Vollmer S., Schendel D., Albert E., Gürtler L, Riethmüller G, Prinz J.C. Evidence for an antigen-specific cellular immune response in skin lesions of patients with psoriasis vulgaris // J Immunol. 1995. -N 155.-p. 4078-4083.

121. Mommers J.M., van Rossum M.M., van Erp P.E., van de Kerkhof P.C. Changes in keratin 6 and keratin 10 (co-)expression in lesional and symptomless skin of spreading psoriasis // Dermatology. 2000. -Vol. 201. - p. 15-20.

122. Mueller W., Hermann B. Cyclosporin A for psoriasis // N Engl J Med. -1976.-Vol. 301.-p. 355.

123. Nanney L.B., Stoscheck C.M., Magid M., King L.E. Jr. Altered 1251. epidermal growth factor binding and receptor distribution in psoriasis // J Invest Dermatol. 1986. -N 86. - p. 260-265.

124. Navarro J.M., Casatorres J., Jorcano J.L. Elements controlling the expression and induction of the skin hyperproliferation-associated keratin K6 // J Biol Chem. 1995. -N 270. - p. 21362-21367.

125. Nickoloff B.J., Karabin G.D., Barker J.N., Griffiths C.E., Sarma V., Mitra R.S., Elder J.T., Kunkel S.L., Dixit V.M. Localization of IL-8 and its inducer tumor necrosis factor-alpha in psoriasis // Am J Pathol. 1991. - Vol. 138, N 1. -p. 129-140.

126. Nickoloff B.J., Wrone-Smith T. Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis // Am J Pathol. 1999. - Vol. 1, N 155. - p. 145-158.

127. Nickoloff B.J., Nestle F.O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities // J Clin Invest. 2004. - Vol. 113, N 12.-p. 1664-1675.

128. Niwa H., Miyazaki J., Smith A.G. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells // Nat Genet. -2000.-N24.-p. 372-376.

129. Ortonne J.P. Recent developments in the understanding of the pathogenesis of psoriasis // Br J Dermatol. 1999. - Vol. 140, N 54. - p. 1-7.

130. Ovigne J.M., Baker B.S., Davison S.C., Powles A.V., Fry L. Epidermal CD8+ T cells reactive with group A streptococcal antigens in chronic plaque psoriasis // Exp Dermatol. 2002. - N 11. - p. 357-364.

131. Paukkonen K., Naukkarinen A., Horsmanheimo M. The development of manifest psoriatic lesions is linked with the invasion of CD8+ T cells and CD11+ macrophages into the epidermis // Arch Dermatol Res. 1992. - N 284. - p. 375379.

132. Pietrzak A.T., Zalewska A., Chodorowska G., Krasowska D., Michalak-Stoma A., Nockowski P., Osemlak P., Paszkowski T., Rolinski J.M. Cytokines and anticytokines in psoriasis // Clin Chim Acta. 2008. - Vol. 394, N 1-2. - p. 7-21.

133. Pillai S., Bikle D.D., Eessalu T.E., Aggarwal B.B., Elias P.M. Binding and biological effects of tumor necrosis factor alpha on cultured human neonatal foreskin keratinocytes // J Clin Invest. 1989. -N 83. - p. 816-821.

134. Premack B.A., Schall T.J. Chemokine receptors: Gateways to inflammation and infection // Nature Med. 1996. - N 2. - p. 1174-1178.

135. Prinz J.C., Gross B., Vollmer S., Trommler P., Strobel I., Meurer M., Plewig G. T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro // Eur J Immunol. 1994. - N 24. - p. 593-598.

136. Prinz J.C., Vollmer S., Boehncke W-H., Menssen A., Laisney I., Trommler P. Selection of conserved TCR-VDJ-rearrangements in chronic psoriatic plaques indicates a common antigen in psoriasis vulgaris // Eur J Immunol. 1999. -N 29. -p. 3360-3368.

137. Prinz J.C. The role of T cells in psoriasis // J Eur Ac Derm Venerol. 2003. -N 17.-p. 257-270.

138. Radlovic N., Janic D., Sajic S., Jankovic S., Jesic M., Lekovic Z., Petrovic R. IPEX syndrome-case report. // Srp Arh Celok Lek. 2008. - Vol. 136, N 9-10. -p. 538-541.

139. Raychaudhuri S.P., Gross J. Psoriasis risk factors: role of lifestyle practices // Cutis. 2000. - N 66. - p. 348-352.

140. Rollins B.J. Chemokines // Blood. 1997. - Vol. 90. N 3. - p. 909-928.

141. Romanelli P., Bouzari N. New clinical syndromes in dermatology // Semin Cutan Med Surg. 2006. - Vol. 25, N 2. - p. 79-86.

142. Russel T.J., Schultes L.M., Kuban D.J. Histocompatibility (HL-A) antigens associated with psoriasis // N Engl J Med. 1972. - N 287. - p. 738-740.

143. Saiag P., Coulomb B., Lebreton C., Bell E., Dubertret L. Psoriatic fibroblasts induce hyperproliferation of normal keratinocytes in a skin equivalent model in vitro // Science. 1985. - N 230. -p. 669-672.

144. Sallusto F., Mackay C.R., Lanzavecchia A. Selective expression of the eotaxin receptor CCR3 by human T helper 2 cells // Science. 1997. - Vol. 5334, N277.-p. 2005-2007.

145. Sallusto F., Lenig D., Mackay C.R., Lanzavecchia A. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes // J. Exp. Med. 1998. - Vol. 187, N 6. - p. 875-883.

146. Sallusto F., Lanzavecchia A., Mackay C.R. Chemokines and chemokine receptors in T cell priming and Thl/Th2-mediated responses // Immunol. Today.1998. Vol. 19, N12.-p. 568-574.

147. Sallusto F., Schaerli P., Loetscher P., Schaniel C., Lenig D., Mackay C.R., Qin S., Lanzavecchia A. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation // Eur. J. Immunol. 1998. - Vol. 28, N9.-p. 2760-2769.

148. Salvarani C., Lo Scocco G., Macchioni P. Prevalence of psoriatic arthritis in Italian psoriatic patients // J Rheumatol. 1995. - N 22. -p. 1499-1503.

149. Sasaki Y., Sakai M., Miyazaki S., Higuma S., Shiozaki A., Saito S. Decidual and peripheral blood CD4+CD25+ regulatory T cells in early pregnancy subjects and spontaneous abortion cases // Molecular Human Reproduction. 2004. - Vol. 10, N5.-p. 347-353.

150. Schaible U.E., Collins H.L., Kaufmann S.H. Confrontation between intracellular bacteria and the immune system // Adv Immunol. 1999. - N 71. - p. 267-377.

151. Schlaak J.F., Buslau M., Jochum W., Hermann E., Girndt M., Gallati H., Meyer zum Biischenfelde K.H., Fleischer В. T cells involved in psoriasis vulgaris belong to the Thl subset// J Invest Dermatol. 1994. - Vol. 102, N 2. - p. 145149.

152. Schroder J.M., Harder J. Human beta-defensin-2 // Int J Biochem Cell Biol. 1999.-N31.-p. 645-651.

153. Shevach E.M., Davidson T.S., Huter E.N., Dipaolo R.A., Andersson J. Role of TGF-beta in the Induction of FOXP3 Expression and T Regulatory Cell Function // J Clin Immunol. 2008. - Vol. 28, N 6. - p. 640-646.

154. Selliah N., Zhang M., White S., Zoltick P., Sawaya B.E., Finkel T.H., Cron R.Q. FOXP3 inhibits HIV-1 infection of CD4 T-cells via inhibition of LTR transcriptional activity // Virology. 2008.- Vol. 381, N 2. - p. 161-167.

155. Singh N.P., Prakash A., Kubba S., Ganguli A., Singh A.K., Sikdar S., Agarwal S.K., Dinda A.K., Grover C. Psoriatic nephropathy-does an entity exist? // Ren Fail.-2005.-Vol. 27, N l.-p. 123-127.

156. Sugiyama H., Gyulai R., Toichi E., Garaczi E., Shimada S., Stevens S.R., McCormick T.S., Cooper K.D. Dysfunctional blood and target tissue146

157. CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation// J Immunol. 2005. - Vol. 174, N1.-p. 164-173.

158. Symington F.W. Lymphotoxin, tumor necrosis factor, and gamma interferon are cytostatic for normal human keratinocytes // J Invest Dermatol. 1989. - N 92. -p. 798-805.

159. Szegedi A., Aleksza M., Gonda A., Irinyi B., Sipka S., Hunyadi J., Antal-Szalmas P. Elevated rate of T helper 1 (T(H)l) lymphocytes and serum IFN-gamma levels in psoriatic patients// Immunol Lett. 2003. - Vol. 86, N 3. - p. 277-280.

160. Tassiulas I., Duncan S.R., Centola M., Theofilopoulos A.N., Boumpas D.T. Clonal characteristics of T cell infiltrates in skin and synovium of patientswith psoriatic arthritis // Hum Immunol. 1999. - N 60. - p. 479-491.

161. Tazi A.R., Camp N.J., Cork M.J., Mee J.B., Keohane S.G., Duff G.W., di Giovine F.S. Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis // Hum Mol Genet. 1999. - N 8. - p. 1135— 1140.

162. Vahlenkamp T.W., Tompkins M.B., Tompkins W.A. The role of CD4+CD25+ regulatory T cells in viral infections // Vet Immunol Immunopathol.- 2005. Vol. 108, N 1-2. - p. 219-225.

163. Valdimarsson H., Baker B.S, Jonsdottir I., Fry L. Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes // Immunol Today.- 1986.-N 7.-p. 256-259.

164. Veale D.J., FitzGerald O. Psoriatic arthritis-pathogenesis and epidemiology // Clin Exp Rheumatol. 2002. - Vol. 20(6 Suppl 28). - p. 27-33.

165. Wang J., van Dongen H., Scherer H.U., Huizinga T.W., Toes R.E. Suppressor activity among CD4+,CD25++ T cells is discriminated by membrane-bound tumor necrosis factor alpha // J Exp Med. 2004. - Vol. 3, N 200. - p. 277285.

166. Werner S., Smola H. Paracrine regulation of keratinocyte proliferation and differentiation // Trends Cell Biol. 2001. - N 11. - p. 143-146.

167. Werner S., Grose R. Regulation of wound healing by growth factors and cytokines // Physiol Rev. 2002. - N 83. -p. 835-870.

168. Wildin R.S., Smyk-Pearson S., Filipovich A.H. Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome // J Med Genet. 2002. - Vol. 39, N 8. - p. 537-545.

169. Wolpe S.D., Cerami A. Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines // FASEB J. 1989. - Vol. 14, N 3. -p. 2565-2573.

170. Zadrazil J., Tichy T., Horak P., Nikorjakova I., Zima P., Krejci K., Strebl P. IgA nephropathy associated with psoriasis vulgaris: a contribution to the entity of 'psoriatic nephropathy' // J Nephrol. 2006. - Vol. 19, N 3. - p. 382-386.

171. Zalewska A., Wyczolkowska J., Dziankowska-Bartkowiak B., Sysa-Jedrzejowska A. Interleukin 4 plasma levels in psoriasis vulgaris patients // Med SciMonit.-2004.-Vol. 10, N4.-p. 156-162.

172. Zalewska A., Glowacka E., Wyczolkowska J., Tchorzewski H., Narbutt J., Sysa-Jedrzejowska A. Interleukin 6 and 8 levels in plasma and fibroblast culturesin psoriasis // Mediators Inflamm. 2006. -Vol. 2006, N 1. - p. 81767.

173. Zhang L., He T., Talal A., Wang G., Frankel S.S., Ho D.D. In vivo distribution of the human immunodeficiency virus/simian immunodeficiency virus coreceptors: CXCR4, CCR3, and CCR5 // J. Virol. 1998. - Vol. 72, N 6. - p. 5035-5045.

174. Zheng Y., Manzotti C.N., Burke F., Dussably L., Qureshi O., Walker L.S., Sansom D.M. Acquisition of suppressive function by activated human CD4+

175. CD25- T cells is associated with the expression of CTLA-4 not FOXP3 // J Immunol.-2008.-Vol. 181, N3.-p. 1683-1691.

176. Zhou Y., Chaplin D.D. Identification in the HLA class I region of a gene expressed late in keratinocyte differentiation // Proc Natl Acad Sci USA. 1993. -N90.-p. 9470-9474.

177. Zlotnik A., Morales J., Hedrick J.A. Recent advances in chemokines and chemokine receptors // Crit. Rev. Immunol. 1999. - Vol. 19, N 1. - p. 1-47.

178. Zou Y.R., Kottmann A.H., Kuroda M., Taniuchi I., Littman D.R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development.//Nature. 1998. - Vol. 6685, N 393. - p. 595-599.

Источник: http://medical-diss.com/medicina/soderzhanie-i-sin...


Сейчас смотрят
Зингер набор для педикюра